Cargando…

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations

Over the past 15 years, three new classes of drugs, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase 4 (DPP‐4) inhibitors and sodium glucose cotransporter‐2 (SGLT‐2) inhibitors have been approved to treat type 2 diabetes based on effects on glycemic control. Although large ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mol, Peter G. M., Thompson, Aliza, Heerspink, Hiddo J. L., Leufkens, Hubert G. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Precision Medicine in Diabetic Kidney Disease. Guest Editor: Hiddo J. L. Heerspink
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220800/ https://www.ncbi.nlm.nih.gov/pubmed/30294953 http://dx.doi.org/10.1111/dom.13453

Ejemplares similares

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives
por: de Vries, Jeroen K., et al.
Publicado: (2018)

The large spectrum of renal disease in diabetic patients
por: Bermejo, Sheila, et al.
Publicado: (2017)

Diabetes mellitus: a single cardiorenal syndrome umbrella
por: Rodríguez, Eva, et al.
Publicado: (2019)

Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
por: Li, Jiahua, et al.
Publicado: (2019)

Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center
por: Yuan, Christina M., et al.
Publicado: (2017)

Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view
por: Pinier, Cédric, et al.
Publicado: (2019)

The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
por: Sarafidis, Pantelis A, et al.
Publicado: (2019)

Long-term outcome in inherited nephrogenic diabetes insipidus
por: Sharma, Sonia, et al.
Publicado: (2018)

Diabetes, deafness and renal disease
por: Godinho, Iolanda, et al.
Publicado: (2017)

Early Treatment With Olmesartan Prevents Juxtamedullary Glomerular Podocyte Injury and the Onset of Microalbuminuria in Type 2 Diabetic Rats
por: Sofue, Tadashi, et al.
Publicado: (2012)

Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future
por: Mallik, Ritwika, et al.
Publicado: (2022)

Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes
por: de Bhailís, Áine M., et al.
Publicado: (2021)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Diabetes mellitus as a cause of end-stage renal disease in Europe: signs of improvement
por: van den Brand, Jan A.J.G.
Publicado: (2016)

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020
por: Bakker, Elisabeth, et al.
Publicado: (2023)

Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2022)

Association between the metabolic profile of serum fatty acids and diabetic nephropathy: a study conducted in northeastern China
por: Liu, Yazhuo, et al.
Publicado: (2022)

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe
por: Koomen, Jeroen V., et al.
Publicado: (2021)

Examining the factors contributing to the association between non-albuminuric CKD and a low rate of kidney function decline in diabetes
por: Buyadaa, Oyunchimeg, et al.
Publicado: (2022)

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
por: von Scholten, Bernt Johan, et al.
Publicado: (2022)

4429 Powering precision medicine research with the efficient construction of large diverse cohorts
por: Petukhova, Lynn, et al.
Publicado: (2020)

Technical Considerations and Confounders for Urine CXCL10 Chemokine Measurement
por: Handschin, Joelle, et al.
Publicado: (2019)

Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital
por: Bardia, Aditya, et al.
Publicado: (2016)

Case Report: Absence of Clinically Significant Recurrent Diabetic Kidney Disease on Postmortem Biopsy 32 Years After Kidney Transplantation for Type 1 Diabetes
por: Nicholl, David D. M., et al.
Publicado: (2021)

4199 A pilot randomized controlled trial of precision care for smoking cessation in the Southern Community Cohort Study
por: Senft, Nicole, et al.
Publicado: (2020)

Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?
por: Nobakht, Ehsan, et al.
Publicado: (2021)

Granulomatous interstitial nephritis and Crohn's disease
por: Timmermans, Sjoerd A.M.E.G., et al.
Publicado: (2016)

Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus
por: Kramer, Anneke, et al.
Publicado: (2016)

Kidney Donors With Diabetes: Renal Biopsy Findings at Time of Transplantation and Their Significance
por: Truong, Luan D., et al.
Publicado: (2019)

Liver Enzymes and the Development of Posttransplantation Diabetes Mellitus in Renal Transplant Recipients
por: Klaassen, Gerald, et al.
Publicado: (2017)

Chronic kidney disease in public renal practices in Queensland, Australia, 2011–2018
por: Hoy, Wendy E., et al.
Publicado: (2022)

Can we routinely measure patient involvement in treatment decision-making in chronic kidney care? A service evaluation in 27 renal units in the UK
por: Durand, Marie-Anne, et al.
Publicado: (2016)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

G1 is the major APOL1 risk allele for hypertension-attributed nephropathy in Central Africa
por: Sumaili, Ernest K, et al.
Publicado: (2018)

4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI)
por: Mosley, Scott, et al.
Publicado: (2020)

The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients
por: Kukla, Aleksandra, et al.
Publicado: (2020)

Effect of Early Steroid Withdrawal on Posttransplant Diabetes Among Kidney Transplant Recipients Differs by Recipient Age
por: Ahn, JiYoon B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8bjf67ooioureov1stgf85t0gu